Associated Papers
Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital.
El Sissy FN et al.
Molecular Diagnosis & Therapy, 2025
Ras, RhoA, and vascular pharmacology in neurodevelopment and aging.
Nussinov R et al.
Neurochemistry International, 2024
Investigating the effects of cysteine-118 oxidation on G12D KRas structure and dynamics: insights from MD simulations.
Salamh S et al.
Journal of Biomolecular Structure & Dynamics, 2024
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Bellone S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants.
Hansen AL et al.
Nature Structural & Molecular Biology, 2023
Mechanism-Based Redesign of GAP to Activate Oncogenic Ras.
Berta D et al.
Journal of the American Chemical Society, 2023
Peptides That Block RAS-p21 Protein-Induced Cell Transformation.
Pincus MR et al.
Biomedicines, 2023
The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms.
Butnariu LI et al.
International Journal of Molecular Sciences, 2022
Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD+ and SIRT3.
Masgras I et al.
Cell Death and Differentiation, 2022
KRAS: A Druggable Target in Colon Cancer Patients.
Negri F et al.
International Journal of Molecular Sciences, 2022
Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK et al.
Journal of Biomolecular Structure & Dynamics, 2022
Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.
Tripathi S et al.
Computational and Structural Biotechnology Journal, 2022
Anticancer drug resistance: An update and perspective.
Nussinov R et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2021
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D et al.
Molecular Cancer, 2021
Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.
Yoshimachi S et al.
Cancer Science, 2021
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K et al.
Scientific Reports, 2020
Costello syndrome: Clinical phenotype, genotype, and management guidelines.
Gripp KW et al.
American Journal of Medical Genetics. Part A, 2019
Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry.
Moghadamchargari Z et al.
Biochemistry, 2019
Catalytically Competent Non-transforming H-RASG12P Mutant Provides Insight into Molecular Switch Function and GAP-independent GTPase Activity of RAS.
Ilter M et al.
Scientific Reports, 2019
RASA1-dependent cellular export of collagen IV controls blood and lymphatic vascular development.
Chen D et al.
The Journal of Clinical Investigation, 2019
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.
Qutob N et al.
Scientific Reports, 2018
Spatial distribution of disease-associated variants in three-dimensional structures of protein complexes.
Gress A et al.
Oncogenesis, 2017
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.
Sogabe S et al.
Acs Medicinal Chemistry Letters, 2017
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.
Lu S et al.
Scientific Reports, 2016
KRAS mutation testing in clinical practice.
Perincheri S et al.
Expert Review of Molecular Diagnostics, 2015
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R et al.
Oncotarget, 2014
Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
Wey M et al.
Biochemistry, 2013
KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability.
Aissi S et al.
Molecular Biology Reports, 2013
Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
Wolf S et al.
Oncogene, 2013
Activated N-Ras signaling regulates arterial-venous specification in zebrafish.
Ren CG et al.
Journal of Hematology & Oncology, 2013
Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.
Vartanian S et al.
The Journal of Biological Chemistry, 2013
Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.
Brossier NM et al.
Brain Research Bulletin, 2012
Abstracts of the International Society for Cellular Oncology 2012 Conference, Joint Meeting with the European Workshop on Cytogenetics, and Molecular Genetics of Solid Tumors. March 4-8, 2012. Palma, Mallorca.
Unknown Author
Cellular Oncology (dordrecht, Netherlands), 2012
A vertically stacked, polymer, microfluidic point mutation analyzer: rapid high accuracy detection of low-abundance K-ras mutations.
Han K et al.
Analytical Biochemistry, 2011
HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
Niihori T et al.
Journal of Human Genetics, 2011
Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer.
Lee WS et al.
International Journal of Surgical Pathology, 2011
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.
Lo HW
Current Cancer Drug Targets, 2010
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
Smith G et al.
British Journal of Cancer, 2010
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
Rauen KA et al.
American Journal of Medical Genetics. Part A, 2010
Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.
Cutts BA et al.
Blood, 2009
Dissection of the GTPase mechanism of Ras protein by MD analysis of Ras mutants.
Friedman ZY et al.
Proteins, 2005
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.
Chan IT et al.
The Journal of Clinical Investigation, 2004
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation.
Xiao A et al.
Cancer Cell, 2002
Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
Al-Mulla F et al.
The Journal of Pathology, 1999
Ampullary carcinoma-A genetic perspective.
Jayaramayya K et al.
Mutation Research. Reviews in Mutation Research, 0
Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis.
Lin Z et al.
Technology in Cancer Research & Treatment, 0